Helix BioPharma to present L-DOS47 lung cancer research findings at Zurich conference
Dr. Heman Chao, VP Research, will be presenting a poster at the 5th Annual Congress on Recombinant Antibodies Conference, in Zurich Switzerland. The poster entitled “L-DOS47 - a novel lung adenocarcinoma specific immuno-conjugate therapeutic”, highlights the ability of L-DOS47 to target and kill lung tumour cells in vitro and in tumour bearing mice, as well as L-DOS47’s ability to enhance the effect of weakly basic chemotherapeutics.
This entry was posted on Tuesday, June 27th, 2006 at 10:16 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.